Objective: Simple guidelines for calculating efficient sample sizes in cluster randomized trials with unknown intraclass correlation (ICC) and varying cluster sizes.
Introduction
The effects of interventions to improve health or change lifestyle are often evaluated with a cluster randomized trial [1, 2] , also known as group randomized trial [3] . In such a trial, organizations (clusters) are randomly assigned to one of the treatment conditions, and all persons sampled within a given cluster get the same treatment. Examples from primary care are patient-centered care of newly diagnosed diabetes [4] and detection and treatment of depression [5] in general practice. Examples from public health are smoking prevention [6] and stress management [7] in primary school. Cluster randomization is less efficient than individual randomization because outcome variation between clusters, reflected by the so-called intraclass correlation (ICC), increases the sampling error of the treatment effect estimate in a cluster randomized trial [8e11] . However, such trials are needed for logistic reasons or to prevent treatment contamination. Individual assignment is impossible for treatments such as health promotion in classrooms. For other treatments, it may induce serious treatment contamination.
Because cluster randomized trials are less efficient but sometimes the only option, it is important to optimize their efficiency. This is the topic of this article. Sample sizes (number of clusters and number of persons per cluster) will be presented that minimize the sampling error, thereby maximizing test power and precision of estimation, for treatment effects, under the constraint of a given budget for sampling and measuring clusters and persons. Here, budget is in terms of money, but it can also be expressed as time or demands on participants. Equal sample sizes per cluster will first be assumed for simplicity and because they are the most efficient. Later, this assumption is relaxed. To prevent misunderstanding, we emphasize that this
What is new?

Key findings
Efficient sample sizes for a cluster randomized trial can be easily computed given the cost per cluster and cost per person and given a range of realistic intraclass correlations (ICCs).
What this adds to what was known?
We do not need to know the precise ICC, and we can easily compensate for varying cluster sizes. Furthermore, the effect size determines the number of clusters needed but not the sample size per cluster.
What is the implication and what should change now?
Researchers must determine the cost per cluster and cost per person before study design. They must also report these costs and the outcome ICC and variance to improve the planning of future trials.
article is about sampling large clusters such as general practices and sampling persons from these clusters and not about sampling small clusters such as families and then including all its members. The outline of this article is as follows. First, the optimal sample size for a cluster randomized trial is given as a function of the ICC of the outcome and the costs per included cluster and per person. Second, an equation is given to calculate the sample size and the budget needed for a given power and effect size. Third, simple solutions to two problems are given: uncertainty about the ICC and varying cluster sizes. Finally, the theory is applied to a published trial.
Optimal sample size and power calculation
Suppose we have a cluster randomized trial with K clusters of n persons per cluster and a quantitative outcome y like body mass index or a clinical questionnaire score. The data can be analyzed not only by a mixed (multilevel) regression but also by an unpaired t-test on the K cluster means, obtained by averaging individual outcomes within each cluster. The latter method is equivalent to mixed regression of the individual data if the sample size is the same for each cluster and there are no covariates [11] . Varying cluster sizes and covariates are discussed later. In a trial, we want to estimate the treatment effect as precisely, and to test it with as much power, as possible. So a good criterion for the design efficiency is the variance (squared standard error [SE 2 ]) of the estimated treatment effect, which is expressed as follows [8e10]:
Here, s 2 y is the total outcome variance within each treatment arm, nK is the total sample size of the trial, and r is the ICC, which is the proportion of outcome variance that is between clusters rather than between individuals within clusters. The first half of the equation shows that the total variance of the treatment effect is the sum of sampling error between clusters and that within clusters. The factor ½ðn À 1Þr þ 1 in the last half of the equation is known as the design effect (DE) . Dividing the total sample size nK by the DE gives the effective sample size, that is, the sample size needed for individual randomization to have the same power and precision as the cluster randomized trial. If the ICC is 0, the DE is 1 and the SE of the treatment effect with cluster randomization is equal to that with individual randomization, as there is no outcome variation at the cluster level then. As the ICC increases, so do the DE and SE of the treatment effect.
Increasing either the cluster size n or the number of clusters K decreases the SE and thus improves power and precision. Increasing n also increases the DE and is thus less effective than increasing K. On the other hand, increasing the number of clusters K may be very expensive. So the question is, ''What is the best choice of n and K for a given trial?'' This is addressed by optimal design theory [12] : how to find that n and K which minimize the SE in Equation (1), thus maximizing power and precision, for a given total sampling cost? Or equivalently, which n and K minimize the total cost for a target SE, power, and precision? To find this optimal design, we need a function that relates sample size to costs. Assume that inclusion of a cluster into the study costs c units (of money, time, or demands), whereas inclusion of a person in an included cluster costs s units. The budget B needed for K clusters of n persons, ignoring those costs that do not depend on sample size, is then B5cK þ snK5Kðc þ snÞ, where (c þ sn) is the total sampling cost per cluster with sample size n. The optimal design minimizes the SE of the treatment effect as a function of n and K, given the budget constraint B5Kðc þ snÞ. Fig. 1 shows how the SE depends on the cluster size n for various ICC values. The cluster size that gives the smallest SE for a given ICC is the optimal design for that ICC. Note that the SE does not continue to decrease as n increases because an increase of n implies a decrease of K because of the budget constraint. The SE is minimal for the following cluster size [9, 10] :
and the number of clusters then can be calculated as
. So the optimal sample size per cluster decreases as the ICC goes up and increases as the cluster-toperson cost ratio c/s goes up. Because of the budget constraint, the optimal number of clusters shows opposite effects: it goes up with the ICC and goes down as the cost ratio c/s increases. Note that the budget B affects the optimal number of clusters but not the optimal cluster size, which only depends on the ICC and the cost ratio. Fig. 2 shows the relation between the ICC and the optimal cluster size for three cost ratios. Inserting Equation (2) into Equation (1) gives the SE 2 for the optimal design and thus the smallest possible SE and largest possible power and precision, given the budget, sampling costs, outcome variance, and ICC. If that SE is still too large for sufficient power and precision, then the budget must be increased, resulting in more clusters rather than in more persons per cluster (Equation (2)). More specifically, given a cluster size of n persons, the number of clusters K needed for a power (1 À g), two-tailed type I error risk a, and effect size d5 m 1 À m 2 s y where m 1 À m 2 is the mean outcome difference between treatments [13] is given by
where DE is the design effect, Z 1 À g is the 100 (1 À g)th percentile of the standard normal distribution (e.g., 1.28 for a power of 90%), and Z 1 À a / 2 is the 100 (1 À a / 2)th percentile (e.g., 1.96 if a 5 0.05 two tailed). The required budget B is then K (c þ sn), the number of clusters times the total cost per cluster. By substituting Equation (2) for n in Equation (3), we minimize the budget, given the effect size, power, and a. Note that multiplying both sides of Equation (3) by n and then dividing both sides by the DE give the total sample size needed for a standard randomized controlled trial (RCT) without nesting.
Coping with the unknown ICC
As Equation (1) and Fig. 1 show, the SE of the treatment effect increases with the ICC, and so a safe strategy is to use the optimal design for the largest realistic ICC based on published trials. However, this may require a large budget, as it follows from Equation (3) that K and thus B increases with the ICC. A less-expensive and still safe choice is to assume an intermediate ICC like the midpoint of the assumed ICC range, for instance, 0.05 if the range is 0e0.10 as suggested by reviews of ICC values in primary care trials [14, 15] . This leads to a smaller B for a given power and effect size. This can then be used in a twostage design as follows. First, we apply the optimal design and budget needed for the midpoint ICC scenario. Then, we estimate the ICC from the data to recalculate the number of clusters needed, leading to more clusters (which requires more budget) only if the ICC is higher than the midpoint. According to a recent review [16] , the final analysis can usually be done on all data without correction for this interim look and sample size recalculation based on the ICC. This review concerned the unpaired t-test in a classic RCT, but it also applies to cluster randomized trials analyzed with a t-test on cluster means, which is equivalent to mixed regression of individual data [11] . Furthermore, a simulation study by Lake et al. [17] (Table 1) suggests that the present two-stage approach is safe in controlling the type I error risk and power.
So instead of taking the number of clusters needed for the maximum possible ICC, we take the number needed for the midpoint ICC, thus saving costs if data analysis of the first stage confirms the midpoint ICC. To see how much can be saved, we computed the percentage extra budget needed for the one-stage design based on the maximum ICC relative to the first stage of the two-stage design based on the midpoint ICC. Fig. 3A shows that much can be saved especially if the ICC range or cost ratio is large. Of course, the actual savings depend on the ICC value obtained in the interim analysis. Fig. 3A shows the savings if the ICC turns out to be smaller than, or equal to, the midpoint so that no second stage is needed. If the ICC is larger, a second stage with extra clusters is needed, increasing the costs for the two-stage design. We therefore also computed the expected Now, there is a chance that the maximum ICC is correct, and then we loose efficiency by choosing the midpoint ICC for the first stage because the optimal design (i.e., cluster size) for the first stage is then not optimal after all. However, this loss is very small. If the maximum ICC is correct, the design based on the midpoint ICC needs at most 5% more budget than the correct design to have the same power and precision, as we verified for all cost ratios between 1 and 50 and for all maximum ICCs from 0.01 to 0.25.
Modifications of the two-stage approach are conceivable. For instance, instead of using the interim ICC point estimate for planning the second stage, one may use the upper boundary of the 95% confidence interval for the ICC to be safe. The price for this safety is a larger number of clusters and a higher budget and [17] suggests that using the point estimate is safe enough. Another modification would be to reestimate the ICC and sample size already during instead of after the first stage and allowing the number of clusters to become smaller instead of larger than initially planned [17] . However, this is beyond the present scope, as our aim is to give simple guidelines for efficient trial design.
In summary, we can save a lot and loose a little by choosing a two-stage design with the first stage based on the midpoint ICC instead of a one-stage design based on the maximum ICC. So the two-stage design is a good choice if clusters are enrolled in stages for logistic reasons anyhow or if stagewise recruitment with sample size reestimation after the first stage is not more expensive than the simultaneous recruitment.
Coping with varying cluster sizes
Our equations assume each of the K clusters to be of the same size. In practice, the cluster size varies because general practices and schools vary in size and because of recruitment problems and individual dropout. Instead of a simple t-test on cluster means, we then need either mixed (multilevel) regression of individual data or weighted least Table 1 . Number of clusters K, cluster size n, and budget B needed by the actual and optimal designs of the diabetes trial, for a power of 90% to detect a treatment effect of size d 5 0.50 (medium), with a 5 5% two tailed, for various cost ratios c/s and ICCs, assuming cost s 5 10 per patient (n and K rounded to the nearest integer; changing s and c while fixing c/s, or changing d, the power, or a, changes both budgets proportionally) squares analysis of cluster means [18] . Furthermore, the cluster size variation causes some efficiency loss. This can be compensated by sampling more clusters. To know how many more clusters, we have to know the relative efficiency (RE) of varying vs. equal cluster sizes. A simple and popular approximation to this RE is based on the assumption of an ICC close to 0 [19e21] . However, this approximation is much too pessimistic, and combining it with an approximation for large ICCs shows that the RE can never be smaller than minRE5 2 2 þ CV 2 [18] . Here, CV is the coefficient of variation (i.e., standard deviation/mean) of the cluster sizes. Another approximation was also derived, by which minRE is 1 À CV 2 / 4, and the accuracy of this result was confirmed for both large [18] and small [22] samples.
Using these two expressions for the minimum RE of varying cluster sizes, minRE, of which the first is still too pessimistic and the second a bit too optimistic, we can adjust for the efficiency loss because of cluster size variation by multiplying the number of clusters with 1/minRE. In practice, the CV of cluster size is typically close to 0.5, for instance, 0.4 in a smoking prevention trial [6] and a stress management trial [7] and 0.6 in a study of general practice size in the United Kingdom [23] . The minRE is then near 0.90, giving an increase of the budget and number of clusters with about 10% only.
Example
Optimal design will be illustrated for a cluster randomized trial on the effect of a training of general practitioners and nurses on the lifestyle and clinical status of patients with newly diagnosed type 2 diabetes [4] . The trial included 41 general practices and 250 patients, giving an average cluster size of 6. Anticipated effect size and ICC were not reported, but the ICC was found to be 0.05 for body mass index and clinical status as measured by percentage of glycated hemoglobin, two of the outcomes. No information on the cost ratio c/s is available from this trial, and the only publication stating costs that we know of reports a cost ratio of 26 [24] (p. 165). So let us start with a cost ratio of 20 and compare the optimal and actual designs. We then consider other cost ratios and ICC values and practical problems and solutions.
Assume as costs c 5 200 per cluster and s 5 10 per person so that the cost ratio is 20. Furthermore, assume an ICC of r 5 0.05 as found in the diabetes trial. The actual design with 41 practices of six included patients each then needs a budget B 5 10,660 (GBP, Euro, USD). The optimal sample size per practice is, however, n 5 19 patients by Equation (2), which allows the inclusion of K 5 27 clusters for almost the same budget, that is, B 5 10,530. Following Equation (1), the optimal design has a DE of 1.90 and effective sample size of (27 Â 19) / 1.9 5 270 patients, giving a power of 90% to detect an effect d 5 0.40. To have this same power, the actual design with n 5 6 patients per practice needs 57 instead of 41 practices, requiring a budget B 5 14,820, which is 41% more than that needed by the optimal design. It can be shown that this ratio of the budgets needed for both designs does not depend on the effect size, power, type I error rate, or absolute costs c and s but depends only on the cost ratio c/s and the ICC. This is just one example, assuming a cost ratio of 20 and an ICC of 0.05. To compare the actual and optimal designs in a more systematic way, Table 1 lists the number of practices and the budget needed for both designs to have a power of 90% for an effect size d 5 0.50 (medium effect size [13] ) at a two-tailed type I error rate of 0.05 for various ICC values and cost ratios. In particular, assuming the ICC and costs of the diabetes example, we need 35 clusters of six patients (actual) or 17 clusters of 19 patients (optimal), requiring a budget B 5 9,100 (actual) vs. B 5 6,630 (optimal). More generally, note that the optimal sample size per practice is between 7 and 70 for all cost ratios from 5 to 50 and all ICCs from 0.01 to 0.10 (Equation (2)). The actual sample size per practice was on average 6 in the diabetes trial [4] compared with 110 in a depression trial [5] , suggesting room for improvement in trial design.
Let us now turn to the problem of an unknown ICC for planning the diabetes trial, assuming as before costs c 5 200 and s 5 10, an effect size d 5 0.50, a power of 90%, and a 5 0.05 two tailed. Take at first, the pessimistic design for an ICC of 0.10. Following Table 1 , we need K 5 28 clusters of size n 5 13, giving a total cost B 5 9,240. The midpoint design for an ICC of 0.05 requires K 5 17 clusters of size n 5 19, with a total cost B 5 6,630, which is only 72% of the pessimistic design. Now suppose the ICC turns out to be 0.10 so that the midpoint design was too optimistic. Its actual DE is then not 1.90 but 2.80, and it follows from Equation (3) that we need a second stage to increase the number of clusters to K 5 25. The total cost for the midpoint design is then 9,750, which is only 5.5% more expensive than the pessimistic design. Now, with respect to the effect of cluster size variation, as no information about this variation was available from the diabetes trial, assume a typical CV of 0.50. The resulting loss of efficiency is then restored by adding about 10% extra clusters, which in turn requires a budget increase of about 10%.
Apart from the problems of an unknown ICC and varying cluster size, two other practical problems need to be discussed. First, the outcome variance and the ICC are never known beforehand and always estimated from the data in the final analysis. As a consequence, the test statistic for the treatment effect follows a Student t-distribution with df 5 K À 2 [11] , giving slightly less power than by Equation (3), which assumes a z-distribution. Calculations for K from 10 to 100 and for power levels of 80% and 90% show that this power loss is compensated by increasing the number of clusters by two if a 5 0.05 or by four if a 5 0.01 two tailed. In the diabetes example, assuming again an effect size d 5 0.50, ICC 5 0.05, costs c 5 200 and s 5 10, a power of 90%, and a 5 0.05 two tailed, the number of clusters thus becomes K 5 19 instead of 17 (optimal) and 37 instead of 35 (actual), requiring budgets B 5 7,410 (optimal) and 9,620 (actual), respectively.
Finally, the optimal design may not be feasible. For instance, it may be difficult to include the optimal number of patients per practice within the time frame of the study. This can then be compensated by including more practices. Or, there may not be enough general practices within reachable distance. A larger sample size per practice then offers some compensation, although the increasing DE destroys part of the gains obtained by a larger n (Equation (1)). Fortunately, as Fig. 1 shows, the SE curves are flat near their minima, and so a modest deviation from the optimal design hardly affects the power and precision. This is also visible in Table 1 , where the actual n 5 6 for the diabetes trial is hardly more expensive than the optimal n 5 10 for a cost ratio of 5 and ICC of 0.05. So if the optimal design is not feasible, one can choose from all feasible designs the one which is closest to the optimal design in terms of K and n and adapt either K or n (whichever can be adapted) to approximate the power for the optimal design. This can be done with Equation (3), which gives the number of clusters K needed for a given cluster size n, whether this n is the optimum according to Equation (2) or not. Equation (3) can also be rewritten such that it gives the required cluster size n for a given number of clusters K (see equation (14) in the study by Hemming et al. [25] ).
Discussion
This article showed how efficient sample sizes for cluster randomized trials can be obtained in a simple way. The optimal sample size per cluster only depends on the clusterto-person cost ratio c/s and on the ICC and is between 7 and 70 if the cost ratio is between 5 and 50 and the ICC is between 0.01 and 0.10. The number of clusters, and thereby also the sampling budget, additionally depends on the effect size and power. Using the diabetes trial as example, we showed that substantive cost reductions can be obtained by optimal design. Simple and efficient solutions were furthermore given for practical problems in sample size calculation. The problem of an unknown ICC can be handled by a two-stage design, with the first stage using the optimal design for the ICC value halfway the range of plausible values. The second stage is only needed if the analysis of the first-stage data shows the ICC to be larger than initially assumed. Furthermore, the loss of power because of cluster size variation can be compensated by sampling 10% more clusters. This article focuses on quantitative outcomes, but almost the same equations apply to binary outcomes [26, 27] . Furthermore, adding covariates can improve power by reducing unexplained outcome variance but hardly affects our equations [27] .
Just like any other study, this one has limitations to be overcome by further work. We assumed two treatment arms, absence of repeated measures, and homogeneity of variances and costs between arms. Ongoing work is on treatment-dependent costs and variances, factorial designs where two treatments are combined, as in the smoking prevention trial [6] , and trials with repeated measures, as in the stress management trial [7] . As a simple example of this work, it can be shown that if the treatment-to-control cost ratio is p (O0), both for the cost per cluster level and for the cost per person, then the optimal treatment-to-control allocation ratio of clusters is p À1/2 . So, for instance, if treatment is four times as expensive as control, then we must assign twice as many clusters to control as to treatment.
As will be clear by now, efficient design of cluster randomized trials depends on the availability of information about outcome variance and sampling cost at each level of the design (cluster and person). It is therefore important that publications of cluster randomized trials report not only the size and significance of the treatment effect of interest but also the outcome variance, ICC, and sampling costs.
